Tardive dyskinesia (TD) is a condition that was first described nearly 60 years ago. Despite the tremendous amount of research on pathophysiology and numerous follow-up studies to understand the course and prognosis of TD, effective treatment of the condition contin- ued to elude us until recently.
Methods
We review and summarize clinical literature on TD, as well as provide an update on new treatments available.
Results
The emergence of tetrabenazine as a treatment modality decreased suffering and improved quality of life for patients. New agents such as valbenazine, deutetrabenazine, and branched-chain amino acids continue to provide relief to patients, without the troublesome side effects of tetrabenazine.
Conclusions
There continues to be a substantial prevalence rate for the condition with the use of first-generation and second-generation antipsychotics. Because of the potential irreversible nature, legal implication, and high prevalence of TD, we advocate for more research on new treatments for the disorder.
Get full access to this article
View all access options for this article.
References
1.
SchoneckerM.Paroxysmal dyskinesia as the effect of megaphen [in German]. Nervenarzt. 1957;28:550–553.
2.
JesteDVWyattRJ. Understanding and treating tardive dyskinesia. New York, NY: Guilford Press; 1982:10–38.
LernerPPMiodownikCLernerV.Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin Neurosci. 2015;69:321–334.
5.
LernerVMiodownikC.Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82:643.
6.
LernerVMiodownikCShevaB. Evidencebased guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81:1967.
7.
MossHBGreenA.Neuroleptic-associated dysphagia confirmed by esophageal manometry. Am J Psychiatry. 1982;139:515–516.
8.
GuptaSEganMFHydeTM. An unusual presentation of tardive dyskinesia with prominent involvement of the pectoral musculature. Biol Psychiatry. 1993;33:291–292.
9.
FaheemADBrightwellDRBurtonGC. Respiratory dyskinesia and dysarthria from prolonged neuroleptic use: tardive dyskinesia? Am J Psychiatry. 1982;139:517–518.
10.
SimpsonGMVargaELeeJH. Tardive dyskinesia and psychotropic drug history. Psychopharmacology (Berl). 1978;58:117–124.
11.
ScheifesAWalravenSStolkerJJ. Movement disorders in adults with intellectual disability and behavioral problems associated with use of antipsychotics. J Clin Psychopharmacol. 2016;36: 308–313.
12.
PreskornSHMacalusoM.Determining whether a definitive causal relationship exists between aripiprazole and tardive dyskinesia and/or dystonia in patients with major depressive disorder, part 3: clinical trial data. J Psychiatr Pract. 2016;22:117–123.
13.
O'BrienA.Comparing the risk of tardive dyskinesia in older adults with first-generation and second- generation antipsychotics: a systematic review and metaanalysis. Int J Geriatr Psychiatry.2016;31:683–693.
14.
GibsonAC. Incidence of tardive dyskinesia in patients receiving depot neuroleptic injection. Acta Psychiatr Scand. 1981;291:111–116.
15.
MukherjeeSRosenAMCardenasC. Tardive dyskinesia in psychiatric outpatients: a study of prevalence and association with demographic, clinical, and drug history variables. Arch Gen Psychiatry. 1982;39:466–469.
16.
CaligiuriMPLacroJPRockwellE. Incidence and risk factors for severe tardive dyskinesia in older patients. Br J Psychiatry. 1997;171:148–153.
17.
de Jesus MariJ, LimaMS, CostaAN, . The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. Eur Arch Psychiatry Clin Neurosci. 2004;254:356–361.
YagiGOgitaKOhtsukaN. Persistent dyskinesia after long-term treatment with neuroleptics in Japan: its present status and clinical problems. Keio J Med. 1976;25:27–35.
20.
BellRCSmithRC. Tardive dyskinesia: characterization and prevalence in a statewide system. J Clin Psychiatry. 1978;39:39–47.
21.
PerrisCDimitrijevicPJacobssonL. Tardive dyskinesia in psychiatric patients treated with neuroleptics. Br J Psychiatry. 1979;135:509–514.
22.
AlexopoulosGS. Lack of complaints in schizophrenics with tardive dyskinesia. J Nerv Ment Dis. 1979;167: 125–127.
23.
JesteDVPotkinSGSinhaS. Tardive dyskinesia—reversible and persistent. Arch Gen Psychiatry. 1979;36:585–590.
24.
CorrellCUSchenkEM. Tardive dyskinesia and new antipsychotics. Curr Opinion Psychiatry. 2008;21:151–156.
25.
CorrellCUKaneJM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol. 2007;17:647–656.
26.
CorrellCULeuchtSKaneJM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414–425.
27.
WoernerMGCorrellCUAlvirJM. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naive patients. Neuropsychopharmacology. 2011;36:1738–1746.
28.
KaneJMSmithJM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry.1982;39:473–481.
29.
SmithJMBaldessariniRJ. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry. 1980;37:1368–1373.
30.
WoernerMGAlvirJMSaltzBL. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 1998;155:1521–1528.
31.
YassaRJesteDV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull. 1992;18:701–715.
32.
KaneJMWoernerMLiebermanJ.Tardive dyskinesia: prevalence, incidence, and risk factors. Psychopharmacology Suppl. 1985;2:72–78.
33.
MukherjeeSRosenAMCaracciG. Persistent tardive dyskinesia in bipolar patients. Arch Gen Psychiatry. 1986;43:342–346.
GanziniLCaseyDEHoffmanWF. Tardive dyskinesia and diabetes mellitus. Psychopharmacol Bull. 1992;28:281–286.
36.
GanziniLHeintzRTHoffmanWF. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. Arch Gen Psychiatry. 1991;48:259–263.
HeinzRRayasamKKrishnanKR. MRI scans in patients with tardive dyskinesia. Biol Psychiatry. 1988; 24:852–857.
39.
MionCCAndreasenNCArndtS. MRI abnormalities in tardive dyskinesia. Psychiatry Res. 1991;40:157–166.
40.
BaribeauJLaurentJPDécary A. Tardive dyskinesia and associated cognitive disorders: a convergent neuropsychological and neurophysiological approach. Brain Cogn. 1993;23:40–55.
41.
CohenHCohenD.What may be gained from neuropsychological investigations of tardive dyskinesia?Brain Cogn. 1993;23:1–7.
GurejeO.Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: relationship to demographic, clinical, treatment, and neuropsychological variables. J Neurol Neurosurg Psychiatry. 1988;51:1525–1530.
44.
WegnerJTCatalanoFGibralterJ. Schizophrenics with tardive dyskinesia. Neuropsychological deficit and family psychopathology. Arch Gen Psychiatry. 1985;42:860–865.
45.
LernerVMiodownikC.Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment. Curr Psychiatry Rep. 2011;13:295–304.
46.
FentonWS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry. 2000, 61(suppl 4):10–14.
47.
WhittyPFOwoeyeOWaddingtonJL. Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology. Schizophr Bull. 2009;35:415–424.
48.
BombinIArangoCBuchananRW. Significance and meaning of neurological signs in schizophrenia: two decades later. Schizophr Bull. 2005;31:962–977.
49.
HeinrichsDWBuchananRW. Significance and meaning of neurological signs in schizophrenia. Am J Psychiatry. 1988;145:11–18.
50.
EmsleyRTurnerHJOosthuizenPP. Neurological abnormalities in first-episode schizophrenia: temporal stability and clinical and outcome correlates. Schizophr Res. 2005;75:35–44.
51.
FlashmanLAFlaumMGuptaS. Soft signs and neuropsychological performance in schizophrenia. Am J Psychiatry. 1996;153:526–532.
52.
GurejeO.Tardive dyskinesia in schizophrenics. Prevalence, distribution and relationship to neurological “soft” signs in Nigerian patients. Acta Psychiatr Scand. 1987;76:523–528.
53.
GuptaSAndreasenNCArndtS. Neurological soft signs in neuroleptic-naive and neuroleptic-treated schizophrenic patients and in normal comparison subjects. Am J Psychiatry. 1995;152:191–196.
54.
KingDJWilsonACooperSJ. The clinical correlates of neurological soft signs in chronic schizophrenia. Br J Psychiatry. 1991;158:770–775.
55.
KangUJBurkeREFahnS.Natural history and treatment of tardive dystonia. Mov Disord. 1986;1:193–208.
56.
CaseyDE. Tardive dyskinesia: reversible and irreversible. Psychopharmacology Suppl. 1985;2:88–97.
57.
ChouinardGBradwejnJ.Reversible and irreversible tardive dyskinesia: a case report. Am J Psychiatry. 1982;139:360–362.
58.
GardosGColeJORapkinRM. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures. Arch Gen Psychiatry. 1984;41:1030–1035.
59.
GlazerWMMorgensternHSchoolerN. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry. 1990;157:585–592.
60.
FernandezHHKruppBFriedmanJH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology. 2001;56:805–807.
61.
ZutshiDCloudLJFactorSA. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic. Tremor Other Hyperkinet Mov (N Y). 2014;4:266.
62.
VinuelaAKangUJ. Reversibility of tardive dyskinesia syndrome. Tremor Other Hyperkinet Mov (N Y). 2014;4:282.
63.
LeeHJKangSG. Genetics of tardive dyskinesia. Int Rev Neurobiol. 2011;98:231–264.
64.
SeemanP.Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets. 2006;10: 515–531.
65.
RemingtonGKapurS.Antipsychotic dosing: how much but also how often?Schizophr Bull. 2010;36:900–903.
66.
GuptaSMosnikDBlackDW. Tardive dyskinesia: review of treatments past, present, and future. Ann Clin Psychiatry. 1999;11:257–266.
67.
LohrJBCadetJLLohrMA. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. Schizophr Bull. 1988;14:291–296.
68.
ElkashefAMRuskinPEBacherN. Vitamin E in the treatment of tardive dyskinesia. Am J Psychiatry. 1990;147:505–506.
69.
DabiriLMPastaDDarbyJK. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am J Psychiatry. 1994;151:925–926.
70.
EganMFHydeTMAlbersGW. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry. 1992;149:773–777.
71.
AdlerLAPeselowERotrosenJ. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry. 1993;150:1405–1407.
72.
AdlerLAPeselowEDuncanE. Vitamin E in tardive dyskinesia: time course of effect after placebo substitution. Psychopharmacol Bull. 1993;29:371–374.
73.
ShriquiCLBradwejnJAnnableL. Vitamin E in the treatment of tardive dyskinesia: a doubleblind placebo-controlled study. Am J Psychiatry. 1992;149:391–393.
74.
LohrJBCaligiuriMP. A double-blind placebo- controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry. 1996;57:167–173.
75.
AdlerLARotrosenJEdsonR. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry. 1999;56:836–841.
76.
AdlerLAEdsonRLavoriP. Long-term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiatry. 1998;43:868–872.
77.
SajjadSH. Vitamin E in the treatment of tardive dyskinesia: a preliminary study over 7 months at different doses. Int Clin Psychopharmacol. 1998;13:147–155.
78.
SchmidtMMeisterPBaumannP.Treatment of tardive dyskinesia with vitamin E. Eur Psychiatry. 1991;6:201–207.
79.
Soares-WeiserKMaayanNMcGrathJ.Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;(2):CD000209. doi: 10.1002/14651858.CD000209.pub2.
LoonenAJVerweyHARoelsPR. Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A negative, doubleblind, placebo-controlled trial. J Clin Psychopharmacol. 1992;12:39–42.
82.
DuncanEAdlerLAngristB. Nifedipine in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1990;10:414–416.
83.
ReiterSAdlerLAngristB. Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patients. J Clin Psychiatry. 1989;50:26–27.
84.
AdlerLDuncanEReiterS. Effects of calcium- channel antagonists on tardive dyskinesia and psychosis. Psychopharmacol Bull. 1988;24:421–425.
85.
StedmanTJWhitefordHAEylesD. Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients. J Clin Psychopharmacol. 1991;11:43–47.
86.
SuddathRLStrawGMFreedWJ. A clinical trial of nifedipine in schizophrenia and tardive dyskinesia. Pharmacol Biochem Behav. 1991;39:743–745.
87.
SmallJGMilsteinVMarhenkeJD. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry. 1987;48:263–267.
88.
TammingaCAThakerGKMoranM. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry. 1994, 55(suppl B):102–106.
89.
SpivakBMesterRAbesgausJ. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry. 1997;58:318–322.
90.
DurifFDebillyBGalitzkyM. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology. 2004;62:381–388.
91.
BassittDPLouzã Neto MR. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci. 1998;248:209–211.
92.
HazariNKateNGroverS.Clozapine and tardive movement disorders: a review. Asian J Psychiatr. 2013;6:439–451.
93.
LiebermanJASaltzBLJohnsCA. The effects of clozapine on tardive dyskinesia. Br J Psychiatry. 1991;158:503–510.
94.
BurumaOJRoosRABruynGW. Tiapride in the treatment of tardive dyskinesia. Acta Neurol Scand. 1982;65:38–44.
95.
GreilWAubergerSHaagH. Tiapride: effects on tardive dyskinesia and on prolactin plasma concentrations. Neuropsychobiology. 1985;14:17–22.
96.
LeblhuberF.Treatment of permanent tardive dyskinesia with tiapride, a selective D2-receptor blocking agent. Clin Neuropharmacol. 1987;10:458–461.
97.
LeblhuberFReiseckerFBengesserG.Tiapride in the treatment of irreversible tardive dyskinesia— initial experiences [in German]. Z Gerontol. 1987;20: 49–51.
98.
MurphyDJHughesGShawGK. Tiapride in tardive dyskinesia. Psychopharmacol Bull. 1982;18:13–16.
99.
PerényiA, AratóM, BagdyG, . Tiapride in the treatment of tardive dyskinesia: a clinical and biochemical study. J Clin Psychiatry. 1985;46:229–231.
100.
PollakPGaioJMHommelM. Effects of tiapride in tardive dyskinesia. Psychopharmacology (Berl). 1985;85:236–239.
101.
RoosRAde HaasEJ, BurumaOJ, . Pharmacokinetics of tiapride in patients with tardive dyskinesia and Huntington's disease. Eur J Clin Pharmacol. 1986;31:191–194.
102.
RoosRAVan der VeldeEA, BurumaOJ, . Assessment of the therapeutic range of tiapride in patients with tardive dyskinesia. J Neurol Neurosurg Psychiatry. 1986;49:1055–1058.
103.
RustM.Use of tiapride in persistent tardive dyskinesia following treatment with neuroleptics [in German]. MMW Munch Med Wochenschr. 1983;125:461–462.
104.
CaseyDEGerlachJ.Sulpiride and oxiperomide in tardive dyskinesia. Trans Am Neurol Assoc. 1979;104:210–211.
105.
CaseyDEGerlachJSimmelsgaardH.Sulpiride in tardive dyskinesia. Psychopharmacology (Berl). 1979;66: 73–77.
106.
SchwartzMMoguillanskyLLanyiG. Sulpiride in tardive dyskinesia. J Neurol Neurosurg Psychiatry. 1990;53:800–802.
107.
ZarebinskiJMRoydsJN. Sulpiride in tardive dyskinesia. S Afr Med J. 1990;78:374–375.
108.
AnderssonUHaggströmJENilssonMI. Remoxipride, a selective dopamine D2 receptor antagonist, in tardive dyskinesia. Psychopharmacology (Berl). 1988;94:167–171.
109.
RichardsonMABevansMLReadLL. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry.2003;160:1117–1124.
110.
RichardsonMASmallAMReadLL. Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. J Clin Psychiatry.2004;65:92–96.
111.
RichardsonMASuckowRWhittakerR. The plasma phenylalanine/large neutral amino acid ratio: a risk factor for tardive dyskinesia. Psychopharmacol Bull. 1989;25:47–51.
112.
Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology.2006;66:366–372.
113.
PodurgielSJNunesEJYohnSE. The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor. Neurosci. 2013;250:507–519.
114.
LeungJGBredenEL. Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother. 2011;45:525–531.
115.
SnellAPClearyMSambrookM.Treatment of tardive dyskinesia with choline and tetrabenazine. Postgrad Med J. 1980;56:663–664.
116.
KazamatsuriHChienCPColeJO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry. 1973;130:479–483.
117.
OndoWGHannaPAJankovicJ.Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999;156:1279–1281.
118.
DorseyERBrochtAFNicholsPE. Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study. J Huntingtons Dis. 2013;2:509–515.
KlawansHLJr, McKendallRR.Observations on the effect of levodopa on tardive lingual-facial-buccal dyskinesia. J Neurol Sci.1971;14:189–192.
140.
SethiSSharmaLNKhannaR.Low dose levodopa in tardive dyskinesia. Indian J Psychiatry. 1990;32:241–243.
141.
ShoulsonI.Carbidopa/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia. Adv Neurol. 1983;37:259–266.
142.
SimpsonGMYadalamKGStephanosMJ. Doubleblind carbidopa/levodopa and placebo study in tardive dyskinesia. J Clin Psychopharmacol. 1988, 8(suppl 4): 49S-51S.
143.
DavisKLBergerPAHollisterLE. Letter: choline for tardive dyskinesia. New Engl J Med. 1975;293:152.
144.
DavisKLHollisterLEBarchasJD. Choline in tardive dyskinesia and Huntington's disease. Life Sci. 1976;19:1507–1515.
145.
GelenbergAJDoller-WojcikJCGrowdonJH. Choline and lecithin in the treatment of tardive dyskinesia: preliminary results from a pilot study. Am J Psychiatry. 1979;136:772–776.
146.
BrancheyMHBrancheyLBBarkNM. Lecithin in the treatment of tardive dyskinesia. Commun Psychopharmacol. 1979;3:303–307.
147.
GelenbergAJDorerDJWojcikJD. A crossover study of lecithin treatment of tardive dyskinesia. J Clin Psychiatry. 1990;51:149–153.
148.
GrowdonJHGelenbergAJDollerJ. Lecithin can suppress tardive dyskinesia. New Engl J Med. 1978;298:1029–1030.
149.
JacksonIVDavisLGCohenRK. Lecithin administration in tardive dyskinesia: clinical and biomedical correlates. Biol Psychiatry. 1981;16:85–90.
150.
JacksonIVNuttallEAIbeIO. Treatment of tardive dyskinesia with lecithin. Am J Psychiatry. 1979;136:1458–1460.
151.
Pérez-CruetJ, MenéndezI, Alvarez-GhersiJ, . Double-blind study of lecithin in the treatment of persistent tardive dyskinesia. Bol Asoc Med P R. 1981;73:531–537.
152.
WilburKKulikAVBrechtTC. Lecithin for tardive dyskinesia. Am J Psychiatry. 1982;139:1375.
153.
KojimaTYamauchiTMiyasakaM. Treatment of tardive dyskinesia with ceruletide: a double-blind, placebo-controlled study. Psychiatry Res. 1992;43:129–136.
154.
MatsunagaTOhyamaSTakeharaS. The effect of ceruletide on tardive dyskinesia: a double-blind place bo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:533–539.
155.
NishikawaTTanakaMKogaI. Biphasic and long-lasting effect of ceruletide on tardive dyskinesia. Psychopharmacolog (Berl). 1985;86:43–44.
156.
NishikawaTTanakaMTsudaA. Treatment of tardive dyskinesia with ceruletide. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:803–812.
157.
NishikawaTTanakaMTsudaA. Ceruletide for tardive dyskinesia. Biol Psychiatry. 1987;22:797–798.
158.
BeneckeRConradBKlingelhöfer J. Successful treatment of tardive and spontaneous dyskinesias with corticosteroids. Eur Neurol. 1988;28:146–149.
159.
SandykRBamfordCRKhanI. L-tryptophan in neuroleptic-induced tardive dyskinesia. Int J Neurosci. 1988;42:127–130.
160.
BjorndalN, CaseyDE, GerlachJ.Enkephalin, morphine, and naloxone in tardive dyskinesia. Psychopharmacology (Berl).1980;69:133–136.
161.
BlumIMunitzHShalevA. Naloxone may be beneficial in the treatment of tardive dyskinesia. Clin Neuropharmacol.1984;7:265–267.
162.
BlumINisipeanuPFRobertsE.Naloxone in tardive dyskinesia. Psychopharmacology (Berl). 1987;93:538.
163.
LindenmayerJPGardnerEGoldbergE. High- dose naloxone in tardive dyskinesia. Psychiatry Res. 1988;26:19–28.
164.
NewhousePATariotPNGrossM. Failure of high dose naloxone to relieve tardive dyskinesia. J Clin Psychopharmacol. 1987;7:364–365.
165.
SandykRSniderSR. Naloxone and tardive dyskinesia. Biol Psychiatry. 1985;20:1335–1336.
166.
StoesslAJPolanskiEFrydryszakH.The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia. Mov Disord. 1993;8:445–452.
167.
BonaJR. Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series. J Clin Psychopharmacol. 2006;26:215–216.
168.
KonitsiotisSPappaSMantasC. Levetiracetam in tardive dyskinesia: an open label study. Mov Disord. 2006;21:1219–1221.
169.
McGavinCLJohnVMusserWS. Levetiracetam as a treatment for tardive dyskinesia: a case report. Neurology. 2003;61:419.
170.
WoodsSWSaksaJRBakerCB. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69:546–554.
171.
LiebermanJAAlvirJMukherjeeS. Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy. Arch Gen Psychiatry. 1989;46:908–913.
172.
FehrCDahmenNKlaweC. Piracetam in the treatment of tardive dyskinesia and akathisia: a case report. J Clin Psychopharmacol. 2001;21:248–249.
173.
KabesJSikoraJStaryO. Effectiveness of piracetam in tardive dyskinesia - double-blind cross-over controlled trial with a placebo [in Czech]. Cesk Psychiatr. 1983;79:339–345.
174.
LibovIMiodownikCBersudskyY. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2007;68:1031–1037.
175.
HuangCCWangRIHasegawaA. Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia. Psychopharmacology (Berl). 1981;73:359–362.
176.
AsnisGMLeopoldMA. A single-blind study of ECT in patients with tardive dyskinesia. Am J Psychiatry. 1978;135:1235–1237.
177.
BessonJAPalinAN. Tardive dyskinesia, depression and ECT. Br J Psychiatry. 1991;159:446.
178.
ChackoRCRootL.ECT and tardive dyskinesia: two cases and a review. J Clin Psychiatry.1983;44: 265–266.
179.
HayDPHayLBlackwellB. ECT and tardive dyskinesia. J Geriatr Psychiatry Neurol. 1990;3:106–109.
180.
LererB.ECT and tardive dyskinesia. J Clin Psychiatry.1984;45:188.
181.
SandykR.The relationship between ECT responsiveness and subtypes of tardive dyskinesia in bipolar patients. Int J Neurosci. 1990;54:315–319.
182.
DamierPThoboisSWitjasT; French Stimulation for Tradive Dyskinesia (STARDYS) Study Group. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry.2007;64:170–176.
183.
EltahawyHAFeinsteinAKhanF. Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: a case report. Mov Disord. 2004;19: 969–972.
184.
KefalopoulouZPaschaliAMarkakiE. A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation. Acta Neurol Scand. 2009;119:269–273.
185.
KoselMSturmVFrickC. Mood improvement after deep brain stimulation of the internal globus pallidus for tardive dyskinesia in a patient suffering from major depression. J Psychiatr Res. 2007;41:801–803.
186.
MentzelCLTenbackDETijssenMA. Efficacy and safety of deep brain stimulation in patients with medication-induced tardive dyskinesia and/or dystonia: a systematic review. J Clin Psychiatry. 2012;73:1434–1438.
187.
SchraderCPeschelTPetermeyerM. Unilateral deep brain stimulation of the internal globus pallidus alleviates tardive dyskinesia. Mov Disord. 2004; 19:583–585.
188.
SpindlerMAGalifianakisNBWilkinsonJR. Globus pallidus interna deep brain stimulation for tardive dyskinesia: case report and review of the literature. Parkinsonism Relat Disord. 2013;19:141–147.
189.
MargoleseHCFerreriF.Management of conventional antipsychotic-induced tardive dyskinesia. J Psychiatr Neurosci. 2007;32:72.
190.
MargoleseHCChouinardGKolivakisTT. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry. 2005;50:703–714.
191.
MargoleseHCChouinardGKolivakisTT. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry. 2005;50:541–547.
192.
MasandPSMagoR.Second-generation antipsychotics and the metabolic syndrome. Curr Psychiatry Rep. 2005;7:153–154.
193.
NarasimhanMMasandP.Metabolic syndrome in patients with schizophrenia: CATIE results. Curr Psychiatry Rep. 2006;8:213–214.
194.
MasandPSSchwartzTLWangX. Prescribing conventional antipsychotics in the era of novel antipsychotics: informed consent issues. Am J Ther. 2002;9:484–487.
195.
FrankBGuptaSMcGlynnDJ. Psychotropic medications and informed consent: a review. Ann Clin Psychiatry. 2008;20:87–95.
196.
GuptaSFrankBMadhusoodananS.Tardive dyskinesia: legal issues and consent. Psychiatr Ann. 2002;32:245–248.
197.
RoseVL. APA practice guideline for the treatment of patients with schizophrenia. Am Fam Physician. 1997;56:1217–1220.
